Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2026)
Amylyx Pharmaceuticals' (AMLX) quarterly Retained Earnings came in at $240000.0 in Q1 2026, up 100.04% year-on-year from $119977.6 in Q1 2025, and up 100.03% quarter-over-quarter from -$751.4 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Retained Earnings history runs 6 years deep, the most recent figure standing at $240000.0 for Q1 2026.
- On a quarterly basis, Retained Earnings rose 100.04% year-over-year to $240000.0 in Q1 2026; TTM through Mar 2026 was $240000.0, a 100.04% increase from a year earlier, with the FY2025 full-year figure at -$751.4 million, down 23.86% from the prior year.
- Retained Earnings grew to $240000.0 in Q1 2026 per AMLX's latest filing, from -$751.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $551000.0 in Q2 2025 and bottomed at -$751.4 million in Q4 2025.
- The 5-year median for Retained Earnings is -$311.5 million (2022), against an average of -$284.7 million.
- Across the five-year window, Retained Earnings sank 3935877.78% in 2022 and jumped 668.04% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$354.2 million in 2022, then jumped by 100.06% to $197000.0 in 2023, then plunged by 308065.48% to -$606.7 million in 2024, then declined by 23.86% to -$751.4 million in 2025, then surged by 100.03% to $240000.0 in 2026.
- Per Business Quant, the three latest AMLX Retained Earnings figures stand at $240000.0 (Q1 2026), -$751.4 million (Q4 2025), and -$718.4 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | 240,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 240,000.00 |
| Dec 31, 2025 | -751.43 Mn |
| Sep 30, 2025 | -718.43 Mn |
| Jun 30, 2025 | 551,000.00 |
| Mar 31, 2025 | -642.60 Mn |
| Dec 31, 2024 | -606.69 Mn |
| Sep 30, 2024 | -569.15 Mn |
| Jun 30, 2024 | -97,000.00 |
| Mar 31, 2024 | -77,000.00 |
| Dec 31, 2023 | 197,000.00 |
| Sep 30, 2023 | -151,000.00 |
| Jun 30, 2023 | -330.57 Mn |
| Mar 31, 2023 | -352.65 Mn |
| Dec 31, 2022 | -354.22 Mn |
| Sep 30, 2022 | -311.50 Mn |
| Jun 30, 2022 | -196,000.00 |
| Mar 31, 2022 | -203.70 Mn |
| Dec 31, 2021 | 9,000.00 |